Profit before interest, taxes and amortization: BeyondSpring (BYSI)

Graphic logo of BeyondSpring (BYSI)

BeyondSpring Inc. (BYSI) current capital depends on trial stages, as stable cash flow is absent. However, the development of agents to mitigate chemotherapy side effects promises monopoly income due to patents. Flexibility is ensured through the outsourcing of production and research. The operating earnings trend visualizes business efficiency, where 0.00 reflects the latest metric value.

BeyondSpring Inc. (BYSI) - Operating profit EBITDA from 11/23/2025 to 11/09/2026

Summary analytical data breakdowns for BeyondSpring (BYSI)

- stock quotes and analyst forecast:
Price Performance Chart BeyondSpring Inc|BYSI - Price Target Chart
- company stock exchange capitalization indicators:
Market Value BeyondSpring|BYSI - Total Company Value
- book capitalization data:
Equity per Share BeyondSpring|BYSI - Book Capitalization|Market Cap to Net Assets Ratio beyondspringpharma.com|BYSI - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Capital BeyondSpring Inc.|BYSI - Long-Term Debt to Equity|Short-Term Debt to Equity BeyondSpring, Inc.|BYSI - Company Debts|Debts to Book Value BeyondSpring|BYSI - Company Long-Term Debts|Short-Term Indebtedness BeyondSpring|Immediate Liquidity beyondspringpharma.com
- earnings and valuation multiples indicators:
BYSI - Net Income|Expected Net Income BeyondSpring Inc.|BYSI - Price to Earnings Ratio|Market Cap to Future Earnings Ratio beyondspringpharma.com|BYSI - PEG Multiple|Business Value to Operating Income Before Depreciation BeyondSpring|BYSI - Operating profit EBITDA|Net earnings per one share for the last twelve months BeyondSpring|BYSI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months beyondspringpharma.com|BYSI - Earnings growth in current year|Earnings growth forecast for next year BeyondSpring Inc.
Analysis of all company metrics:BeyondSpring Inc.
Manufactured product of BeyondSpring, Inc.

The low predictability of cash flows for BeyondSpring Inc. (BYSI) stems from the pharmaceutical business's dependence on regulatory decisions and the market success of oncology drugs. Analyzing EBITDA allows for an assessment of the actual speed of cash generation, establishing a basis for calculating multiples and eliminating reporting time lags, which is critical during the volatile commercialization of new developments.

Who BeyondSpring Inc. competes with

Income before deduction of interest, taxes and amortization INCY|HCM - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization nuvationbio.com|Day One Biopharmaceuticals (DAWN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MNPR|INBX (Inhibrx Biosciences Inc) - Operating profit EBITDA|Operating profit before deduction of amortization I-Mab Inc. (IMAB)|Profit before payment of interest, taxes and amortization Fennec Pharmaceuticals (FENC)|HRTX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Nuvectis Pharma NVCT|Coherus - Profit before payment of interest, taxes and amortization|CRBP - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Cardiff Oncology, Inc.|BCAB: Operating profit EBITDA|Operating profit before depreciation charges lixte.com LIXT|Operating profit before deduction of amortization CTXR|Profit before interest, taxes and amortization Cellectar Biosciences Inc CLRB|Operating profit before deduction of amortization BLRX (BioLineRx Corp)|CANF (Can-Fite) - Income before deduction of interest, taxes and amortization|Aprea Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization KZIA (Kazia Therapeutics Ltd)|Silexion - Operating profit EBITDA|Income before deduction of interest, taxes and amortization NCNA (NuCana plc)|CMRX: Operating profit EBITDA|Profit before interest, taxes and amortization Cyclacel, Inc. (CYCC)|Profit before payment of interest, taxes and amortization G1 Therapeutics Inc.|KRON: Income before deduction of interest, taxes and amortization|Operating profit EBITDA KTRA|Operating profit EBITDA Oncternal Therapeutics Inc (ONCT)|Profit before payment of interest, taxes and amortization Portage PRTG